for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Incyte Says Phase 3 Data From True-Ad Program Of Ruxolitinib Cream Support Planned Submission Of NDA To US FDA In 2020

April 5 (Reuters) - Incyte Corp:

* FIRST PRESENTATION OF PHASE 3 DATA FROM TRUE-AD PROGRAM OF RUXOLITINIB CREAM AT REVOLUTIONIZING ATOPIC DERMATITIS VIRTUAL SYMPOSIUM

* DATA SUPPORT PLANNED SUBMISSION OF A NEW DRUG APPLICATION (NDA) TO U.S. FOOD AND DRUG ADMINISTRATION BEFORE END OF 2020

* RUXOLITINIB CREAM RESULTED IN RAPID, ROBUST CLINICAL RESPONSE, WITH SIGNIFICANTLY MORE PATIENTS ACHIEVING IGA TREATMENT SUCCESS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up